Literature DB >> 20659305

A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype.

E Galmozzi1, B Del Menico, R Rametta, P Dongiovanni, A L Fracanzani, L Benedan, V Borroni, P Maggioni, S Fargion, L Valenti.   

Abstract

Recently, genome-wide association studies in patients affected by HCV infection have identified a strong association between sustained virological response to peg-interferon/ribavirin and spontaneous viral clearance and common single nucleotide polymorphisms (SNPs) near the IL28B gene, encoding for interferon-lambda-3. Thus, it is anticipated that IL28B genotype determination will be integrated in clinical practice to guide treatment decisions. Here, we describe a simple tetra-primer amplification refractory mutation system polymerase chain reaction (T-ARMS-PCR) for the evaluation of the rs12979860 C>T IL28B SNP, for which strong evidence of association with clinical outcomes has been collected in subjects of European descent. Valid genotypic data were obtained for over 99% of subjects analysed, and T-ARMS-PCR procedures were validated by the analysis of DNA samples of 164 patients with chronic HCV infection. In conclusion, this method allows rapid, reproducible, inexpensive and accurate detection of rs12979860 polymorphism without need of any special equipment and is also suitable for evaluation of a low number of samples on a routine basis.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659305     DOI: 10.1111/j.1365-2893.2010.01349.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.

Authors:  Kieron B L Lim; Hamid R Sima; M Isabel Fiel; Viktoriya Khaitova; John T Doucette; Maria Chernyiak; Jawad Ahmad; Nancy Bach; Charissa Chang; Priya Grewal; Leona Kim-Schluger; Lawrence Liu; Joseph Odin; Ponni Perumalswami; Sander S Florman; Thomas D Schiano
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

2.  Allele-specific PCR for determination of IL28B genotype.

Authors:  Linda Cook; Kurt Diem; Woo Kim; John D Scott; Keith R Jerome
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

3.  IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity?

Authors:  Luca Valenti; Edoardo Pulixi; Susanna La Spina
Journal:  Hepatol Int       Date:  2011-12-07       Impact factor: 6.047

4.  The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.

Authors:  Zobair M Younossi; Aybike Birerdinc; Mike Estep; Maria Stepanova; Arian Afendy; Ancha Baranova
Journal:  J Transl Med       Date:  2012-02-07       Impact factor: 5.531

5.  Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus.

Authors:  Abolfazl Fateh; Mohammadreza Aghasadeghi; Seyed D Siadat; Farzam Vaziri; Farzin Sadeghi; Roohollah Fateh; Hossein Keyvani; Alireza H Tasbiti; Shamsi Yari; Angila Ataei-Pirkooh; Seyed H Monavari
Journal:  Osong Public Health Res Perspect       Date:  2015-11-30

6.  One-Step ARMS-PCR for the Detection of SNPs-Using the Example of the PADI4 Gene.

Authors:  Sabrina Ehnert; Caren Linnemann; Bianca Braun; Josephine Botsch; Karolin Leibiger; Philipp Hemmann; And Andreas K Nussler
Journal:  Methods Protoc       Date:  2019-07-25

7.  Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.

Authors:  Alessio Aghemo; Elisabetta Degasperi; Maria Grazia Rumi; Enrico Galmozzi; Luca Valenti; Raffaele De Francesco; Stella De Nicola; Cristina Cheroni; Eleonora Grassi; Massimo Colombo
Journal:  Biomed Res Int       Date:  2013-07-09       Impact factor: 3.411

8.  Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

Authors:  Paola Dongiovanni; Quentin M Anstee; Luca Valenti
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C.

Authors:  Camila da Silva Ferreira; Rodrigo Martins Abreu; Marlone Cunha da Silva; Aline Siqueira Ferreira; Paulo Dominguez Nasser; Flair José Carrilho; Suzane Kioko Ono
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.